The global rodent surgery services market is valued at USD 420 million in 2025 and is projected to reach USD 942 million by 2034, a compound annual growth rate of 9.4% across the forecast period, according to Contrive Datum Insights. Revenue is expected to stand at USD 459 million in 2026, the first year of the forecast.
The market covers the surgical creation and preparation of mouse and rat models for preclinical research. That includes disease-induction procedures such as tumor implantation and cardiovascular or metabolic surgery, as well as the pre-implantation of telemetry devices, osmotic pumps and vascular or intrathecal cannulas before a study begins. The product is a live, surgically prepared animal ready for a research protocol, not a device or a reagent. Work is done either in a sponsor's own vivarium or by a specialist contract provider, and buyers include pharmaceutical and biopharmaceutical companies, contract research organizations and academic or government research institutes running drug discovery, safety and efficacy studies.
The study names the outsourcing of surgical model creation to contract research organizations as the largest single contributor to growth, and rates its impact high. The lines most exposed to it are the ones pulling ahead of the market. Outsourced and contract surgical services already account for 61% of 2025 revenue, or USD 256.2 million.
By type, Pathological Model is the larger line, holding 63% of 2025 revenue at USD 264.6 million and still 58% in 2034. It grows at 8.41%, below the market as a whole. Pre-Implanted Model grows at 10.93%, the fastest of any type, and its share climbs from 37% to 42% as its value rises from USD 155.4 million to USD 395.64 million. Among buyers, Pharmaceutical/Biopharmaceutical Companies lead with 44% of 2025 revenue, worth USD 184.8 million, while Contract Research Organizations grow fastest at 10.61%. Mice account for 58% of revenue at USD 243.6 million, and Rats are the faster grower at 10.34%. Oncology is the leading indication at 34%, or USD 142.8 million.
Geographically, North America leads with 42% of 2025 revenue, USD 176.4 million, rising to USD 348.54 million by 2034. Asia Pacific gains ground steadily, moving from 22% of global revenue in 2025 to 28% in 2034 as its revenue grows from USD 92.4 million to USD 263.76 million. Middle East and Africa stays the smallest region, at 4% in 2025 and 4.5% by 2034. The United States is the largest single country market at USD 149.94 million, or 35.7% of the 2025 total.
The forecast carries two clear risks. A sustained pullback in biopharma R&D spending would slow how quickly sponsors commission new surgical models, and longer animal welfare review timelines would limit how many procedures providers can complete. If both occur, the study's bear case holds 2034 revenue to USD 847.8 million. If outsourcing penetration speeds up, contract research capacity in Asia Pacific opens ahead of schedule and biopharma budgets hold, the bull case lifts 2034 revenue to USD 1036.2 million.
The report, titled "Rodent Surgery Services Market Size, Share & Industry Analysis," segments the market across five axes: type, application, animal type, indication and service model. It gives revenue and growth rates for every line in every year from 2020 to 2034, covers all five regions with country-level breakdowns, and includes the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.